Abstract
(1)Parenteral low molecular weight heparins like enoxaparin, dalteparin, tinzaparin, synthetic heparin derivatives fondaparinux, direct thrombin inhibitors like lepirudin, bivalirudin, argatroban, oral anticoagulants like Dabigatran, Rivaroxiban are newer anticoagulants. The emergence of new oral anticoagulants has the advantage over old drugs is their predictable pharmacokinetics, pharmacodynamics properties, adverse effects clinically less relevant and their different mechanism of action.
Clinically these new anticoagulant drugs are preferred for prophylaxis of patients undergoing hip or knee surgery to prevent deep vein thrombosis, after the replacement of heart valve, open- heart surgery to prevent clot formation and for therapy of pulmonary embolism (synthetic derivatives). Also as an alternative in patients diagnosed with heparin induced thrombocytopenia who require anticoagulation(2).